Enfermedades retinianas y nuevas terapias

Foto de Enfermedades retinianas y nuevas terapias

Foto de University of Paris-Sorbonne

University of Paris-Sorbonne

París, Francia

Publicaciones en colaboración con investigadores/as de University of Paris-Sorbonne (5)

2024

Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
Ophthalmic research, Vol. 67, Núm. 1, pp. 311-321
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2
Ophthalmology, Vol. 131, Núm. 8, pp. 914-926

2023

Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
The Lancet, Vol. 402, Núm. 10411, pp. 1449-1458

2022

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
The Lancet, Vol. 399, Núm. 10326, pp. 741-755

2017

Long-Term PEDF Release in Rat Iris and Retinal Epithelial Cells after Sleeping Beauty Transposon-Mediated Gene Delivery
Molecular Therapy - Nucleic Acids, Vol. 9, pp. 1-11